Replies to post #155077 on Biotech Values

[oc631]

Well, shortening treatment time and getting rid of riba are still on the table especially since ABBV is also trying 8 weeks combos.

Both companies are pushing real hard to be first to market in GT1 oral. Shorter dosing and riba-free treatment is the secondary endpoint in this race. Are you willing to speculate which company may be first to file an NDA in GT1? First approved?

I personally have no idea.